Please assess the completion status of the following clinical trial:

Trial Title: Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Has type 2 diabetes mellitus~* Has inadequate glycemic control on diet/exercise therapy and oral antihyperglycemic agent monotherapy~Exclusion Criteria:~* History of type 1 diabetes mellitus or a history of ketoacidosis~* History of any of the following medications: Thiazolidinediones (TZD) (for participants whose basal medication is not TZD) and/or insulin within 12 weeks prior to study participation, omarigliptin anytime

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Omarigliptin 25 mg/Sulfonylureas (SUs) (Phase A+B) (Type: EXPERIMENTAL): Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of SUs throughout the duration of the study.
- Omarigliptin 25 mg/Glinides (Phase A+B) (Type: EXPERIMENTAL): Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of glinides throughout the duration of the study.
- Omarigliptin 25 mg/biguanides (BGs) (Phase A+B) (Type: EXPERIMENTAL): Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of BGs throughout the duration of the study.
- Omarigliptin 25 mg/Thiazolidinediones (TZDs) (Phase A+B) (Type: EXPERIMENTAL): Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of TZDs throughout the duration of the study.
- Omarigliptin 25 mg/α-GIs (Phase A+B) (Type: EXPERIMENTAL): Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of α-glucosidase (α-GIs) inhibitors throughout the duration of the study.
- Placebo/SUs (Phase A) → Omarigliptin 25 mg/SUs (Phase B) (Type: PLACEBO_COMPARATOR): Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of SUs throughout the duration of the study.
- Placebo/Glinides (Phase A) → Omarigliptin 25 mg/Gln. (Phase B) (Type: PLACEBO_COMPARATOR): Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of glinides throughout the duration of the study.
- Placebo/BGs (Phase A) → Omarigliptin 25 mg/BGs (Phase B) (Type: PLACEBO_COMPARATOR): Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of BGs throughout the duration of the study.
- Placebo/TZDs (Phase A) → Omarigliptin 25 mg/TZDs (Phase B) (Type: PLACEBO_COMPARATOR): Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of TZDs throughout the duration of the study.
- Placebo/α-GIs (Phase A) → Omarigliptin 25 mg/α-GIs (Phase B) (Type: PLACEBO_COMPARATOR): Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of α-GIs inhibitors throughout the duration of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).